Issues & Trends

Curiosis Inc. Reports Cumulative Third-Quarter Revenue of Approximately 6 Billion… Up 29% Year-Over-Year

"Revenue Growth Accelerates as Full-Scale Shipments of Global ODM Products Begin in the Fourth Quarter"

Kwon Oh Seok
2026-11-16 16:16:08
[Edaily Reporter Kwon Oh Seok ] #Curiosis Inc., a company specializing in autonomous laboratories (SDL/lab automation), has completed its transition to an Original Design Manufacturer (ODM) supply system centered on major global clients and the establishment of large-scale mass production infrastructure, and is set to see a significant jump in earnings in the fourth quarter.
(Photo: Curiosis Inc.)

According to the Financial Supervisory Service’s electronic disclosure system on the 16th, Curiosis Inc.’s cumulative consolidated revenue for the third quarter of this year reached approximately 5.94 billion won, a 29% increase year-over-year, continuing its growth momentum. However, the cumulative operating loss for the same period totaled approximately 6.23 billion won.
The slowdown in profitability during the third quarter is largely characterized as temporary “growing pains” associated with global expansion. This is because transitional costs and deferred revenue were concentrated during the process of restructuring the business model—shifting from an existing sales network centered on small-scale regional distributors to an ODM model that supplies large volumes to global Big Tech companies.
In fact, immediately after signing a large-scale supply contract with a new global ODM client, Company M, in July, the company carried out a distribution network restructuring over the second and third quarters, divesting distribution rights in about 10 countries. In addition, at the request of Revvity, a key global partner, the company is advancing the development of enhanced integrated software that combines remote multi-party collaboration features and an artificial intelligence (AI) analysis engine with its flagship ODM product, “Hawkeye Chrono,” which has caused some shipment schedules to be delayed.
Approximately 1 billion won in preemptive infrastructure investment costs for future growth were also reflected in the cumulative third-quarter results. With the completion of the second phase of the Yongin expansion project—which has an annual production capacity (CAPA) of 100 billion won—last February, a loss on the disposal of tangible assets (approximately 300 million won) resulted from the demolition of the aging Building 1, and costs such as mold manufacturing expenses for four new products and equipment for new global contracts (approximately 500 million won) were treated as one-time expenses.
Efforts to expand the next-generation pipeline and promote open innovation among industry, academia, and research institutes are also gaining momentum. Curiosis Inc. is making steady progress in developing an intelligent incubator—a core component of its autonomous laboratory initiative and one that is applicable to Good Manufacturing Practice (GMP) facilities—and will sequentially launch new models of its “Celloger-ORD” series, an ODM lineup dedicated to organoids, starting at the end of the year.
In addition, joint projects with major institutions and companies—including △MEDIPOST CO., LTD. (establishment of a QC system for cell therapy processes), △Gradiant BioConvergence (optimization of image analysis for patient-derived organoids), and △the AI New Drug Research Institute of the Korea Pharmaceutical and Bio-Pharma Association (creation of an AI-driven new drug development ecosystem)—have also gained momentum.
A Curiosis Inc. official stated, “The temporary revenue delay resulting from the transition to a global ODM partnership, along with the reorganization of our distribution network and investments in mass production infrastructure, were all completed in the third quarter.” The official added, “Starting in the fourth quarter, full-scale mass production and shipment of ODM products will begin for two global companies with which we have already signed contracts, so we expect to see significant quarterly revenue growth and rapid improvements in profitability.”

Economy

Corporation

IT·Science

Economy

[Exclusive] CJ and HDC to Wind Down Biodegradable Plastics Business Launched Jointly After 4 Years

#HDC Hyundai EP and #CJ CheilJedang’s joint venture, CJ HDC BioSol (hereinafter “BioSol”), established to develop biodegradable plastic materials, has begun the process of dissolution. Analysts sugges…
2026-11-16 16:30:04

Corporation

'Balanced Growth in Fashion and Beauty' LF Reports 51.1 Billion Won in Q3 Operating Profit… Up 217%

LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
2026-11-16 16:38:14

IT·Science

Olix Pharmaceuticals, Inc. Expands Development of Adipose Tissue-Targeted Weight-Loss Drug… Plans to File IND Application in the First Half of Next Year

RNA interference (RNAi) drug developer Olix Pharmaceuticals, Inc.(226950)is expanding its research and development of next-generation obesity treatments using adipose tissue-targeted RNAi technology. …
2026-11-16 16:35:03